.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,884,794

« Back to Dashboard

Details for Patent: 6,884,794

Title: Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
Abstract:The invention provides a formulation to be administered as dry powder for inhalation suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering of pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation freely flowable, which can be produced in a simple way, physically and chemically stable and able of delivering either accurate doses and high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.
Inventor(s): Staniforth; John Nicholas (Parma, IT), Vodden Morton; David Alexander (Parma, IT), Gill; Rajbir (Parma, IT), Brambilla; Gaetano (Parma, IT), Musa; Rossella (Parma, IT), Ferrarini; Lorenzo (Parma, IT)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Filing Date:Feb 04, 2003
Application Number:10/257,368
Claims:1. A medicinal powder, comprising: i) a fraction of fine particles, comprising particles of a physiologically acceptable excipient and particles of magnesium stearate, said fraction of fine particles having a mean particle size of less than 35 .mu.m; ii) a fraction of coarse particles, comprising particles of a physiologically acceptable carrier having a particle size of at least 100 .mu.m; and iii) one or more active ingredient in micronised form selected from the group consisting of budesonide and its epimers, formoterol and its stereoisomers, TA 2005 and its stereoisomers, salts thereof, and mixtures thereof, wherein: said fraction of fine particles (i) comprises said physiologically acceptable excipient in an amount of 90 to 99 percent by weight and said magnesium stearate in an amount of 1 to 10 percent by weight; and said fraction of fine particles and said fraction of coarse particles are present in a weight ratio of between 5:95 and 30:70.

2. A powder according to claim 1, wherein said active ingredient is the 22 R epimer of budesonide.

3. A powder according to claim 1, wherein said active ingredient is a combination of formoterol or TA-2005 with (a) a member selected from budesonide and its epimers and (b) beclomethasone dipropionate.

4. A powder according to claim 1, wherein said particles of magnesium stearate partially coat the surface of either said particles of said physiologically acceptable excipient or said particles of said physiologically acceptable carrier.

5. A powder according to claim 1, wherein said fraction of fine particles has a particle size of less than 15 .mu.m.

6. A powder according to claim 1, wherein said particles of said physiologically acceptable carrier have a particle size of at least 175 .mu.m, and said fraction of fine particles and said fraction of coarse particles are present in a weight ratio between 10:90 and 20:80.

7. A powder according to claim 1, wherein said particles of said physiologically acceptable carrier have a fissure index of at least 1.25.

8. A powder according to claim 1, wherein said physiologically acceptable excipient is one or more crystalline sugars.

9. A powder according to claim 1, wherein said physiologically acceptable excipient is .alpha.-lactose monohydrate.

10. A powder according to claim 1, wherein said fraction of coarse particles has a particle size of at least 175 .mu.m.

11. A powder according to claim 1, wherein said fraction of fine particles comprises said physiologically acceptable excipient in an amount of about 98 percent by weight and said magnesium stearate in an amount of about 2 percent by weight.

12. A powder according to claim 1, wherein said fraction of fine particles and said fraction of coarse particles are present in a weight ratio between 10:90 and 20:80.

13. A powder according to claim 1, wherein said physiologically acceptable carrier comprises at least one crystalline sugar.

14. A powder according to claim 1, wherein said physiologically acceptable carrier comprises lactose.

15. A powder according to claim 1, wherein said physiologically acceptable carrier comprises .alpha.-lactose monohydrate.

16. A powder according to claim 1, wherein said magnesium stearate is present in an amount of 0.02 to 1.5% by weight, based on the total weight of said powder.

17. A powder according to claim 1, wherein said magnesium stearate is present in an amount of 0.05 to 1% by weight, based on the total weight of said powder.

18. A powder according to claim 1, wherein said magnesium stearate is present in an amount of 0.1 to 0.6% by weight, based on the total weight of said powder.

19. A powder according to claim 1, wherein said magnesium stearate is present in an amount of 0.2 to 0.4% by weight, based on the total weight of said powder.

20. A powder according to claim 1, which is prepared by a process comprising: a) co-micronising particles of said physiologically acceptable excipient and particles of said magnesium stearate to reduce the particle size of said physiologically acceptable excipient and said magnesium stearate and to obtain a mixture in which said particles of said physiologically acceptable excipient are coated with said magnesium stearate; b) spheronising said mixture by mixing said mixture with said particles of said physiologically acceptable carrier such that particles of said mixture adhere to the surface of said particles of said physiologically acceptable carrier, to obtain speronised particles; c) mixing said active ingredient in micronized form with said spheronised particles.

21. A powder according to claim 20, wherein said co-micronising is carried out by milling.

22. A powder according to claim 21, wherein said milling is carried out with a jet mill.

23. A powder according to claim 1, which is prepared by a process comprising: a) mixing in a high-energy mixer particles of said physiologically acceptable excipient having a starting particle size of less than 35 .mu.m and particles of said magnesium stearate to obtain a mixture in which said particles of said magnesium stearate partially coat the surface of said particles of said physiologically acceptable excipient; b) spheronising said mixture by mixing said mixture with particles of said physiologically acceptable carrier such that particles of said mixture adhere to the surface of said particles of said physiologically acceptable carrier, to obtain spheronised particles; and c) mixing said active ingredient particles in micronised form with said spheronised particles.

24. A powder according to claim 23, wherein said particles of said physiologically acceptable excipient which are mixed with said magnesium stearate have a starting particle size of less than 15 .mu.m.

25. A powder according to claim 1, which is prepared by a process comprising: a) co-mixing particles of said physiologically acceptable carrier, particles of said magnesium stearate and particles of said physiologically acceptable excipient, to obtain a mixture; and b) mixing said active ingredient in micronised form with said mixture, wherein said particles of said physiologically acceptable carrier have a particle size of at least 175 .mu.m and said co-mixing is carried out for at least two hours.

26. A powder according to claim 1, which is in the form of spherical or semispherical units having a core of coarse particles.

27. A process for making a powder according to claim 1, said process comprising: a) co-micronising particles of said physiologically acceptable excipient and particles of said magnesium stearate to reduce the particle size of said physiologically acceptable excipient and said magnesium stearate and to obtain a mixture in which said particles of said physiologically acceptable excipient are coated with said magnesium stearate; b) spheronising said mixture by mixing said mixture with said particles of said physiologically acceptable carrier such that particles of said mixture adhere to the surface of said particles of said physiologically acceptable carrier, to obtain speronised particles; and c) mixing said active ingredient in micronized form with said spheronised particles.

28. A process according to claim 27, wherein said co-micronising is carried out by milling.

29. A process according to claim 28, wherein said milling is carried out with a jet mill.

30. A process for making a powder according to claim 1, said process comprising: a) mixing in a high-energy mixer particles of said physiologically acceptable excipient having a starting particle size of less than 35 .mu.m and particles of said magnesium stearate to obtain a mixture in which said particles of said magnesium stearate partially coat the surface of said particles of said physiologically acceptable excipient; b) spheronising said mixture by mixing said mixture with particles of said physiologically acceptable carrier such that particles of said mixture adhere to the surface of said particles of said physiologically acceptable carrier, to obtain spheronised particles; and c) mixing said active ingredient in micronised form with said spheronised particles.

31. A process according to claim 30, wherein said particles of said physiologically acceptable excipient which are mixed with said magnesium stearate have a starting particle size of less than 15 .mu.m.

32. A process of making a powder according to claim 1, said process comprising: a) co-mixing particles of said physiologically acceptable carrier, particles of said magnesium stearate and particles of said physiologically acceptable excipient, to obtain a mixture; and b) mixing said active ingredient in micronised form with said mixture, wherein said particles of said physiologically acceptable carrier have a particle size of at least 175 .mu.m and said co-mixing is carried out for at least two hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc